Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.57 USD -8.21% Intraday chart for Gritstone bio, Inc. -8.54% +25.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M MT
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial CI
Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from NASDAQ Biotechnology Index CI
B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating MT
Transcript : Gritstone bio, Inc. Presents at First Annual Goldman Sachs Catalyst Clinic, Dec-05-2023 11:00 AM
Earnings Flash (GRTS) GRITSTONE BIO Posts Q3 Revenue $1.6M MT
Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna Vaccine Candidates Against Covid-19 (Part of the Company?s Coral Program) at IDWeek 2023 CI
Gritstone bio Offers Stock Options to Three New Employees MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket MT
Piper Sandler Lifts Price Target on Gritstone bio to $7 From $6, Keeps Overweight Rating MT
Gritstone Bio Gets Contract For Comparative COVID-19 Trial; Shares Jump After-Hours MT
Gritstone Bio, Inc. Receives BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 CI
Gritstone bio, Genevant Sciences Sign License Agreement for Use of LNP Technology MT
Gritstone Bio and Genevant Sciences Announce Option and License Agreement CI
Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $2M MT
Gritstone bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Gritstone Joins Collaborative Cancer Research Initiative; Shares Rise 4% Pre-Bell MT
Moderna/Merck begins late-stage study of skin cancer vaccine combination RE
Gritstone bio, Inc.(NasdaqGS:GRTS) added to Russell Small Cap Comp Value Index CI
Gritstone bio, Inc.(NasdaqGS:GRTS) added to Russell 3000 Index CI
Gritstone bio, Inc.(NasdaqGS:GRTS) added to Russell 3000E Index CI
Gritstone bio, Inc.(NasdaqGS:GRTS) added to Russell Small Cap Completeness Index CI
Gritstone bio, Inc.(NasdaqGS:GRTS) added to Russell 2500 Value Index CI
Chart Gritstone bio, Inc.
More charts
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.8 USD
Average target price
8.8 USD
Spread / Average Target
+214.29%
Consensus
  1. Stock
  2. Equities
  3. Stock Gritstone bio, Inc. - Nasdaq
  4. News Gritstone bio, Inc.
  5. Gritstone bio : Oncology Names New CFO; Chief Technology Officer Roman Yelensky to Step Down